Progression of persistent atrial fibrillation and impact of ablation: A systematic review and meta-analysis.

Heart RhythmMay 21, 2026 (epub)
Clinical ResearchCardiology

Udit Thakur, Souvik Kumar Das, Nitesh Nerlekar et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the progression of persistent atrial fibrillation (PsAF) to permanent atrial fibrillation (AF) in various populations. The study found a pooled progression rate of 16.42 per 100 person-years. Contemporary studies indicated lower progression rates compared to earlier cohorts, highlighting the impact of prior pulmonary vein isolation on reducing progression.

Key findings

  • The pooled progression rate from PsAF to permanent AF was 16.42 per 100 person-years.
  • Contemporary studies showed a progression rate of 11.06 per 100 person-years compared to 21.83 in earlier cohorts.
  • Higher prevalence of prior pulmonary vein isolation was associated with a lower progression rate (rate ratio 0.82).
  • Catheter ablation utilization remains relatively low despite increasing availability.

Why it matters

Understanding the progression of PsAF to permanent AF is crucial for developing effective management strategies. Identifying predictors of progression can help clinicians tailor interventions and improve patient outcomes.

Source

Published in Heart Rhythm. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.